x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011735
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val34 of human ALKBH7 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ALKBH7 |
| UniProt No. | Q9BT30 |
| Gene ID | 84266 |
| Gene Description | The AlkB alkylation repair homolog 7 is a member of the alkylated DNA repair homolog family that is responsible for repair of DNA damage induced by oxidation and alkylation. ALKBH7 is a nuclear encoded protein that contains an amino-terminal mitochondrial targeting sequence that directs import of ALKBH7 to the mitochondria., like other Alkb family members, the ALKBH7 protein lacks a functional nucleotide recognition lid essential for nucleobase-binding, which abrogates any DNA or RNA repair capability. In response to DNA damage, mitochondrial ALKBH7 triggers the collapse of the mitochondrial membrane potential. The resultant loss of mitochondrial function leads to depletion of cellular energy and programmed cell death. Research studies indicate that ALKBH7 knockdown cells are resistant to apoptotic cell death induced by oxidizing and alkylating agents, which suggests that ALKBH7 may play a novel function in promoting cell death. Indeed, ALKBH7 has been identified as a key regulator of the alkylation or oxidizing DNA damaged induced necroptosis pathway. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
